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Background:  An investigational  subunit  vaccine  containing  the varicella-zoster  virus  (VZV)  glycoprotein
E  (gE)  and  the  AS01B adjuvant  system  is being  evaluated  for the  prevention  of  herpes  zoster  (HZ)  in  older
adults.  A phase  II trial evaluating  different  formulations  of  this  vaccine  (containing  25  g, 50 g, or  100  g
gE)  was  conducted  in  adults  ≥60 years  of  age  and  showed  that all formulations  elicited  robust  cellular
and  humoral  immune  responses  for  up  to  3 years  after  vaccination.  In  this  follow-up  study  in  subjects
who  received  two  doses  of  the  50 g  gE/AS01B formulation  (HZ/su),  we  assessed  the  persistence  of  the
immune  responses  for up  to 6 years  after  vaccination.
Methods: This phase  II, open-label,  multicenter,  single-group  trial conducted  in  the  Czech  Republic,
Germany,  Sweden,  and  the  Netherlands  followed  129 subjects  who  had  received  two  doses  (2  months
apart)  of  HZ/su  during  the  initial  trial.  Vaccine-induced  immune  responses  (frequencies  of  gE-speciﬁc
CD4+ T cells expressing  ≥2  activation  markers  and serum  anti-gE  antibody  concentrations)  were  evalu-
ated  at 48,  60,  and  72  months  after the  ﬁrst  HZ/su  dose.
Results:  Six  years  after  vaccination  with  HZ/su,  gE-speciﬁc  cell-mediated  immune  responses  and  anti-gE
antibody  concentrations  had  decreased  by 20–25%  from  month  36, but remained  higher than  the  prevac-
cination  values.  At month  72, the gE-speciﬁc  cell-mediated  immune  response  was  3.8  times  higher  than
+ 6the  prevaccination  value  (477.3  vs. 119.4  activated  gE-speciﬁc  CD4 T cells per  10 cells),  and  the anti-gE
antibody  concentration  was  7.3  times  higher  than  the  prevaccination  value  (8159.0  vs. 1121.3 mIU/mL).
No  vaccine-related  serious  adverse  events  were reported  between  months  36  and  72.
Conclusions:  gE-speciﬁc  cellular  and  humoral  immune  responses  persisted  for  6 years  after  two-dose
vaccination  with  HZ/su  in healthy  older  adults.  No  safety  concerns  were  identiﬁed.
ublis©  2015  The  Authors.  P
. IntroductionHerpes zoster (HZ), or shingles, results from the reactivation
f latent varicella-zoster virus (VZV), usually many years
fter primary VZV infection (chickenpox) that typically occurs
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during childhood [1]. HZ is characterized by a painful unilateral
dermatomal vesicular rash. The most frequent complication is pos-
therpetic neuralgia (persistent pain after resolution of the rash),
which can last for months or years [1,2]. The incidence of HZ
increases with age, and HZ is most frequent in adults aged ≥50 years
[1,2]. Similarly, the incidence of postherpetic neuralgia increases
with age [3]. HZ is also more frequent in persons with immunocom-
promising conditions [2]. Reactivation of latent VZV is believed to
occur when VZV-speciﬁc cell-mediated immunity (CMI) falls below
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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 critical threshold, either because of aging or immunosuppression
1,2,4,5].
A live attenuated vaccine against HZ (Zostavax®, Merck & Co,
nc.), containing a high concentration of the live Oka VZV vaccine
train, is licensed for adults aged ≥50 years [1,6]. However, it is
ontraindicated for immunocompromised persons and its efﬁcacy
gainst HZ decreases with age [3,7]. Efﬁcacy was 63.9% in adults
ged 60–69 years but decreased to 37.6% in adults aged ≥70 years
3]. Moreover, efﬁcacy of Zostavax® against HZ decreases gradu-
lly after vaccination, from 62.0% at year 1 to 43.1% at year 5 in
dults ≥60 years of age [8], and remained statistically signiﬁcant
nly through year 8 after vaccination [9].
Recombinant subunit vaccines are alternatives to live attenu-
ted vaccines, notably because of their high immunogenicity when
dministered with an adjuvant [10]. VZV glycoprotein E (gE) is
n attractive candidate antigen because it is a prominent target
f VZV-speciﬁc CD4+ T-cell responses [11–13]. An investigational
ecombinant subunit vaccine containing VZV gE and the AS01B
djuvant system (GSK Vaccines) is currently being evaluated for
he prevention of HZ in older adults and in patients with immuno-
ompromising conditions. A phase II clinical trial was  conducted
n adults ≥60 years of age to evaluate different formulations of
his candidate vaccine (containing 25 g, 50 g, or 100 g gE com-
ined with AS01B or saline) using different schedules (one or two
oses). This trial showed that two doses of all the adjuvanted vac-
ine formulations in older adults had clinically acceptable safety
roﬁles and elicited robust cellular and humoral immune responses
hat persisted for up to 3 years after vaccination [14]. Furthermore,
mmunogenicity changed little with increasing age [14,15]. Based
n the results of this and other clinical trials [14,15], the 50 g
E/AS01B formulation (herein referred to as HZ/su) was selected
or further clinical development. Recently, a randomized, observer-
lind, placebo-controlled phase III study demonstrated that HZ/su
fﬁcacy against herpes zoster was 97.2% (95% conﬁdence interval,
3.7–99.0) in adults ≥50 years of age after a mean follow-up of 3.2
ears, and that vaccine efﬁcacy did not decrease with increasing
ge [16].
To investigate the potential of this candidate vaccine to provide
ong-term protection against HZ, we assessed the persistence of
accine-induced immune responses between years 4 and 6 after
accination in subjects who received two doses of HZ/su.
. Patients and methods
.1. Study design and subjects
This follow-up study was a phase II, open-label, multicenter, sin-
le group trial conducted in the Czech Republic, Germany, Sweden,
nd the Netherlands (ClinicalTrials.gov, NCT01295320) between
ebruary 28, 2011 and June 20, 2013. This trial followed subjects
ho had received two doses of HZ/su 2 months apart during a
ingle-blind, randomized, controlled trial that was completed in
uly 2010 (ClinicalTrials.gov, NCT00434577) [14]. The study proto-
ol was approved by the national independent ethics committees of
he participating countries and was conducted in accordance with
he Declaration of Helsinki and Good Clinical Practice guidelines.
ritten informed consent was obtained from all subjects before
tudy entry.
All the subjects who had received two doses of HZ/su 2 months
part (i.e., the 50 g gE/AS01B group) in the initial trial were eligible
or inclusion in the follow-up trial. Subjects were excluded if they
ad participated (or planned to participate) in another trial in which
hey were exposed to an investigational or non-investigational
roduct (pharmaceutical product or device) after the end of the
nitial study; had received immunoglobulins or any blood products34 (2016) 863–868
within the 3 months preceding the ﬁrst blood draw; had received a
vaccine containing 3-O-desacyl-4′-monophosphoryl lipid A (MPL)
or Quillaja saponaria Molina, fraction 21 (QS21; Antigenics Inc., a
wholly owned subsidiary of Agenus Inc., Lexington, MA) after the
end of the initial study.
2.2. Study vaccine
No vaccine was  administered in this study. In the initial trial,
the subjects were vaccinated with two doses of HZ/su (GSK Vac-
cines) at months 0 and 2 [14]. HZ/su contains 50 g of VZV gE and
the liposome-based adjuvant system AS01B, which contains the
immunoenhancers MPL  and QS21 (50 g each). The vaccine was
administered intramuscularly (0.5 mL)  in the deltoid region.
2.3. Assessment of immunogenicity
The cellular and humoral immune responses induced by the
vaccine were evaluated in blood samples collected 48, 60, and 72
months after the ﬁrst dose of HZ/su. The frequencies of antigen-
speciﬁc CD4+ T cells expressing at least two  activation markers
among interferon- , interleukin-2, tumor necrosis factor-,  and
CD40 ligand (herein referred to as CD4[2+] T cells) per 106 cells
were measured by intracellular cytokine staining after in vitro
stimulation with gE or with VZV and detection by ﬂow cytometry
as previously described [14]. Serum anti-gE antibody concentra-
tion (mIU/mL) was measured by a GSK in-house enzyme-linked
immunosorbent assay (ELISA) with an assay cut-off of 18 mIU/mL.
2.4. Assessment of safety
Fatal serious adverse events (SAEs), SAEs related to study partici-
pation or study vaccine, potential immune-mediated inﬂammatory
diseases, and suspected HZ episodes were recorded between
months 36 and 72. Subjects were asked to contact the investigator
immediately if they manifested any signs or symptoms that they
believed to be serious or if a suspected HZ rash occurred. In addi-
tion, the investigator asked about the occurrence of AEs at each visit
or contact during the whole study period.
2.5. Statistical analysis
The primary objective of the study was to evaluate cell-mediated
and humoral immune responses to HZ/su in healthy older adults
overall and for each age cohort (60–69 years and ≥70 years of age)
at 48, 60, and 72 months after the ﬁrst dose of HZ/su. The secondary
objectives were to evaluate the safety of HZ/su in healthy older
adults (60–69 years and ≥70 years of age) at months 48, 60, and
72 and to collect clinical data on suspected HZ cases. Only descrip-
tive analyses were performed. Unless otherwise speciﬁed, data are
presented as medians with the ﬁrst and the third quartiles (Q1–Q3).
Immunogenicity was analyzed on the according-to-protocol
(ATP) cohort for immunogenicity, which included all evaluable
subjects excluding those who reported an HZ episode during the
study. The frequency of gE-speciﬁc CD4[2+] T cells was calcu-
lated as the frequency of CD4[2+] T cells upon in vitro stimulation
with gE minus the frequency of CD4[2+] T cells upon stimulation
with medium alone (background). Safety was analyzed on the total
cohort for persistence, which included all subjects.
3. Results3.1. Subjects
Among the 714 subjects enrolled in the initial trial, 166 subjects
were vaccinated with HZ/su (i.e., the 50 g gE/AS01B vaccine group)
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Dig. 1. Participant ﬂow diagram. * One subject discontinued before treatment. The
urrent trial. gE, VZV glycoprotein E; N, number of subjects included in the respecti
nd 147 completed the study to month 36 [14]. Of the 146 subjects
ligible for the current trial, 17 subjects were not willing or able to
articipate. Thus, 129 subjects who had received two  doses of HZ/su
uring the initial trial were enrolled in the current trial (Fig. 1). Of
hese, 57 were from Germany, 32 from Sweden, 26 from the Czech
epublic, and 14 from The Netherlands, and 119 (92.2%) completed
he study. Reasons for withdrawal were lost to follow-up (n = 4), an
AE (death; n = 2), consent withdrawal (n = 2), or inability to attend
 visit (n = 2). Three subjects were excluded from the ATP cohort
or immunogenicity: two subjects received interfering concomitant
edications and one subject reported an HZ episode.
Demographic characteristics of subjects enrolled in this long-
erm follow-up study were not different from those of subjects
nrolled in the initial study (Table 1). The mean age of the sub-
ects at ﬁrst vaccination in the total cohort for persistence was 72.8
able 1
emographic characteristics.
Characteristics HZ/su group (n = 129)
Age at ﬁrst
vaccination (years)
Mean (standard deviation) 72.8 (4.96)
Range 60–84
Age category, n (%) 60–69 years 26 (20.2)
≥70 years 103 (79.8)
Sex, n (%) Female 78 (60.5)
Male 51 (39.5)
Ethnicity, n (%) White–Caucasian 128 (99.2)
African Heritage–African
American
1 (0.8)gray frame represents the initial trial (Chlibek et al. [14]) and the white frame, the
ording-to-protocol cohorts; S, saline.
years (range, 60–84 years). Most subjects were ≥70 years of age
(n = 103, 79.8%). The overall proportion of women was 60.5%, and
all but one subject was Caucasian (99.2%).
3.2. Cell-mediated immune responses
In the initial study, the frequency of gE-speciﬁc CD4[2+] T cells
peaked at month 3 (i.e., one month after the second HZ/su vac-
cination) and decreased by approximately 50% at month 12 [14].
During the course of the current study, the CMI  response began
to plateau beginning approximately 48 months after the ﬁrst vac-
cine dose. The median CD4[2+] T cell frequencies (per 106 cells)
decreased by approximately 25% between month 36 (640.0; Q1–Q3,
403.0–1405.4) and month 72 (477.3; Q1–Q3, 231.4–1037.0), but
they remained higher than the prevaccination level (119.4; Q1–Q3,
67.8–286.9) (Fig. 2A). At month 72, the median gE-speciﬁc CMI
response was  still 3.8 times higher than the prevaccination value.
The frequencies of gE-speciﬁc CD4[2+] T cells decreased in both
age groups in parallel but they were generally lower in subjects
≥70 years of age than in those 60–69 years of age (Fig. 2B).
Similarly, the median frequencies of VZV-speciﬁc CD4[2+] T cells
decreased by 42% between month 36 (555.5; Q1–Q3, 266.7–998.2)
and month 72 (322.7; Q1–Q3, 180.1–667.0) (data not shown).
3.3. Humoral immune responsesAll subjects were seropositive for anti-gE antibodies before
vaccination [14] and remained positive at all time points after
vaccination up to month 72. Median anti-gE antibody concentra-
tions were highest at month 3 and appeared to level off starting
866 R. Chlibek et al. / Vaccine 34 (2016) 863–868
Fig. 2. gE-speciﬁc cell-mediated immune responses after two doses of HZ/su. The
median frequencies of CD4+ T cells expressing at least two  activation markers
(among CD40 ligand, interleukin-2, tumor necrosis factor-˛, and interferon-) per
106 cells after in vitro stimulation with gE were measured by intracellular cytokine
staining followed by ﬂow cytometry. (A) Overall population. The dashed line repre-
s
a
E
a
2
t
t
t
h
6
a
3
a
C
f
s
e
i
c
d
c
S
O
Fig. 3. Anti-gE humoral immune response after two  doses of HZ/su. Anti-gE anti-
body concentrations were determined by enzyme-linked immunosorbent assay.
(A)  Overall population. The dashed line represents the prevaccination value. (B)
By  age group. Black dots with solid line presents age cohort 60–69 years, whiteents the prevaccination value. (B) By age group. Black dots with solid line presents
ge  cohort 60–69 years, white dots with dashed line presents age cohort ≥70 years.
rror bars indicate the ﬁrst and the third quartiles.
t about month 24, with a gradual decrease by approximately
0% between months 36 and 72 (Fig. 3A). Antibody concentra-
ions remained above prevaccination values for up to 6 years after
he ﬁrst vaccination. At month 72, the anti-gE antibody concen-
ration (8159.0 mIU/mL; Q1–Q3, 5451.2–12212.4) was  7.3 times
igher than the prevaccination value (1121.3 mIU/mL; Q1–Q3,
24.2–2309.0). Anti-gE concentrations in both age groups (60–69
nd ≥70 years of age) were similar (Fig. 3B).
.4. Safety
Four SAEs were reported in three subjects between months 36
nd 72. One subject had anemia and a concomitant acute ﬂare of
rohn’s disease, both of which resolved. The two  other SAEs were
atal: one subject died from a cardiovascular event and the other
ubject died of an unknown cause. None of the SAEs were consid-
red related to vaccination by the investigators.
Two subjects, both ≥70 years of age, developed a potential
mmune-mediated disease following vaccination with HZ/su: one
ase of polymyalgia rheumatica and the case of Crohn’s disease
escribed above. The former occurred more than 4 years after vac-
ination and the latter more than 5 years after vaccination. Both
AEs were considered unrelated to vaccination by the investigators.
ne 89-year-old subject reported a suspected HZ episode duringdots with dashed line presents age cohort ≥70 years. Shown are median antibody
concentrations. Error bars indicate the ﬁrst and the third quartiles.
this long-term follow-up, more than 5 years after vaccination. The
episode lasted for 15 days and the patient recovered without seque-
lae.
4. Discussion
This study adds an additional 36 months of immunopersistence
data following vaccination with HZ/su to the previously reported
results [14]. Together, the initial and current studies provide a 72-
month follow-up assessment of the persistence of the immune
responses induced by two  doses of HZ/su and show that these
immune responses persist for up to 6 years in healthy older adults.
Both cell-mediated and humoral immune responses were high-
est at one-month following the second vaccine dose and then
declined until they began to level off at about month 24 (for the
humoral response) or month 48 (for the cell-mediated response).
Most of the decline in both cellular and humoral responses occurred
during the ﬁrst year following vaccination. The cell-mediated and
humoral gE-speciﬁc immune responses remained above the pre-
vaccination levels through month 72. These are currently the
longest immunopersistence data available for HZ/su. Given the
results of this study, even longer follow-up will be required to
experimentally determine the durability of humoral and cellular
immune responses to HZ/su. Additionally, the available data may
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e used to model the long-term persistence of HZ/su immune
esponses.
The immune responses to the HZ/su vaccine in subjects vacci-
ated at age 60–69 years and ≥70 years were comparable at all time
oints, indicating little impact of age on either the peak immune
esponse levels or the persistence of cellular and humoral immune
esponses to HZ/su. These ﬁndings are consistent with those of
revious studies using different schedules or formulations of the
djuvanted gE subunit vaccine candidate [15,17]. This also suggests
hat HZ/su is able to overcome the effects of immune senescence,
hich is believed to contribute to reduced immune responses to
ome vaccines in older adults [18,19]. However, in the absence of
n established immunological threshold of protection for HZ [20],
 correlation between the immune response levels described here
nd clinical protection against HZ should not be inferred. Although
he ﬁrst phase III study of HZ/su showed that the vaccine had 97.2%
fﬁcacy against herpes zoster in adults ≥50 years of age approxi-
ately after 3 years of follow up [16], long-term follow-up studies
ill be needed to determine the duration of the protection induced
y HZ/su, especially in older adults who respond less well to vac-
ination in general and for whom the medical need is the greatest
5,21].
The HZ/su vaccine had a clinically acceptable safety proﬁle
n this population of older adults. Over the whole study period,
eported SAEs were consistent with expectations for this popula-
ion of adults aged 60 years or older at the time of vaccination,
uch as cardiovascular disorders and cancers [22]. No SAEs were
onsidered related to vaccination. Also, no safety concerns related
o immune-mediated diseases were identiﬁed between month 36
nd month 72. These results are consistent with those observed
uring the 36 month follow-up period of the initial study [14].
This study has some limitations. First, the study was  open and
nly subjects vaccinated with HZ/su were included. Thus, the per-
istence of the immune responses could be compared only to
ubjects’ prevaccination levels and not to a control group. Second,
his study was conducted in healthy immunocompetent adults,
hich may  not fully represent the overall older population. It is
orth noting, however, that HZ/su has demonstrated its ability to
timulate robust immune responses in two different immunocom-
romised populations: HIV-infected adults and adult autologous
ematopoietic stem-cell transplant recipients [23,24]. In addition,
his study was conducted in four European countries with similar
ocio-economic and ethnic characteristics, and other populations
ay  thus respond differently to this vaccine [25]. Finally, although
he number of subjects was sufﬁcient to provide robust immuno-
enicity results, the evaluation of the incidence of SAEs, potential
mmune-mediated diseases, and HZ cases was limited by the small
umber of subjects. Larger studies would be needed to detect rare
Es.
In conclusion, although the cellular and humoral immune
esponses induced by two doses of HZ/su decreased over time,
hey remained substantially above prevaccination levels for 6 years.
hese results suggest that the vaccine may  have the potential to
rovide long-term protection against HZ in older adults, although
his needs to be established in clinical efﬁcacy studies.
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